

Amarantus Bioscience Holdings, Inc.  
Form 8-K  
May 11, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 11, 2015**

**AMARANTUS BIOSCIENCE HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

**000-55016**

**26-0690857**

(State or other jurisdiction of  
incorporation or organization)

(Commission File Number)

IRS Employer

Identification No.)

**655 Montgomery Street, Suite 900**

**94111**

**San Francisco, CA**

(Address of Principal Executive Offices) (Zip Code)

**(408) 737-2734**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Items.**

On May 11, 2015, Amaranthus Bioscience Holdings, Inc. (the “Company”) issued a press release announcing that it has reported preliminary data from the blood-based version of its MSPrecise<sup>(R)</sup> diagnostic, the Company's proprietary multiple sclerosis (MS) diagnostic test. MSPrecise, a next-generation DNA sequencing (NGS) assay, measures DNA mutations found in rearranged immunoglobulin genes in immune cells (B cells) to identify patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation

A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

*(d) Exhibits*

**Exhibit No. Description**

99.1	Amarantus Bioscience Holdings, Inc. Press Release, dated May 11, 2015.
------	--

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**AMARANTUS BIOSCIENCE  
HOLDINGS, INC.**

Date:

May  
11,  
2015

By: */s/ Gerald E. Commissiong*

Name: Gerald E. Commissiong

Title: Chief Executive Officer